Conversely, in the IMvigor210 urothelial carcinoma cohort, MZF1 expression was positively correlated with response to anti-PD-L1 treatment, with high MZF1 expression associated with improved survival and extended overall survival compared to lower expression levels (Figure 6D). The gene discussed is MZF1; the disease is urothelial carcinoma.